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ABSTRACT
Background and the purpose of the study: Indoleamine 2,3-dioxygenase (IDO) suppresses 
adaptive immune response. The purpose of this study was to determine the effect of the IDO 
inhibitor namely 1-methyl-DL-tryptophan (DL-1-MT) on antibody production after vaccination 
with hepatitis B surface (HBs) antigen.
Methods: Four groups of BALB/c mice were immunized with a HBs antigen vaccine. In the first 
group the vaccine had no DL-1-MT, whereas in the other three groups the vaccine contained       
1 mg , 10 mg and 20 mg DL-1-MT. Blood samples were collected 5 weeks post-vaccination and 
anti-HBs antibodies in the serum were measured by ELISA. 
Results: Compared to the three groups of mice that were immunized with the vaccines containing 
DL-1-MT, serum anti-HBs level was much higher in the mice that were immunized with the 
vaccine with out DL-1-MT. 
Conclusions: Inhibition of IDO at the time of vaccination decreased humoral immune response 
to HBs antigen vaccine. The idea that IDO activity is simply immunosuppressive may need to 
be re-evaluated.
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INTRODUCTION
Indoleamine  2,3-dioxygenase  (IDO)  is  a  45  kDa 
enzyme that catalyses the initial rate-limiting step 
of  tryptophan  degradation  along  the  kynurenine 
pathway. IDO is inducible by various inflammatory 
stimuli, mainly interferon-γ, and also IFNs type I, 
tumor  necrosis  factor-α,  and  lipopolysaccharide. 
This enzyme is widely distributed in various cell 
types including the antigen presenting cells (APCs) 
monocytes,  macrophages  and  dendritic  cells.  Its 
expression  in APCs  is  accompanied  by  impaired 
adaptive  immune  response  because  tryptophan 
depletion and kynurenine pathway products in local 
microenviroment  decrease  T-cell  proliferation, 
increase T-cell apoptosis and induce the emergence 
of regulatory T-cells (Tregs) from naïve T-cells (1, 
2). IDO mediated immunosuppression reduces graft 
rejection  (3),  and  ameliorates  the  clinical  course 
of  experimental  autoimmune  diseases  (4).  We 
have recently shown that in hemodialysis patients, 
characterized by impaired adaptive immunity, IDO 
expression is increased and is further increased in 
the non-responders to hepatitis B virus vaccination 
(5).  
Inhibition of T-cell function via IDO is also mediated 
by  non-APC  cell  types.  Expression  of  IDO  in 
paternally derived placental trophoblast contributes 
to success of semi-allogenic pregnancy (6), while 
IDO expressed by tumor cells contributes to escape 
of tumors by immunosurveillance (7). 
In the light of the above data, IDO inhibition seems 
to  be  attractive  in  cases  where  enhancement  of 
adaptive  immunity  is  beneficial.  Clearly,  such  a 
case  is  the  immune  response  to  vaccines  against 
various  infectious  agents.  In  the  present  study 
such  an  approach  was  tested  experimentally  by 
immunizing BALB/c mice with hepatitis B surface 
(HBs) antigen and 1-methyl-DL-tryptophan (DL-1-
MT) was co-administered as an adjuvant. DL-1-MT 
is a competitive, non-toxic IDO inhibitor (8) that has 
been successfully used in vivo to break the immune 
privilege of placenta and tolerance against grafts, 
autoantigens, and tumors (3, 6, 9, 10).
MATERIAL AND METHODS
Animals
Twelve-week  old  female  BALB-c  mice  bred  and 
maintained in the animal facilities of the Research 
Institute  at  the  Theagenion  Anticancer  Hospital 
of  Thessaloniki.  All  studies  were  performed  in 
236accordance  with  the  procedures  issued  by  the 
Institutional Animal Care and Use Committee.
Immunization
Initially, suspensions of DL-1-MT (Sigma-Aldrich, 
St.  Louis,  MO,  USA)  in  incomplete  Freund’s 
adjuvant  (Sigma-Aldrich)  and  solutions  of  HBs 
antigen protein (Adw) (Abcam, Cambridge, UK) in 
phosphate buffer saline (Gibco BRL, Grand Island, 
NY, USA) were prepared. Then equal volumes of 
suspensions  and  solutions  were  mixed  vigorously 
for making the final water-in-oil emulsions, which 
were injected in mice intraperitoneally at a volume 
of 200 µl.  
Four groups of animals, 10 per each group, were 
immunized.  In  all  groups  the  injected  emulsions 
contained 2 µg of HBs antigen protein (Adw). In the 
first control group the emulsion had no DL-1-MT, 
whereas in the other 3 groups the amount of DL-1-
MT was 1 mg, 10 mg and 20 mg respectively.
Determination  of  antibodies  against  hepatitis  B 
surface antigen
Five weeks after immunization blood samples were 
collected  from  the  heart  of  anaesthetized  animals 
and serum was stored at -20°C. 
Antibodies against HBs antigen (anti-HBs) in the 
serum were measured by means of ELISA (Mouse 
Anti-HBsAg  IgG  ELISA  Assay,  Express  Biotech 
International, Thurmont,  MD,  USA)  according  to 
the manufacturer instructions with the exception of 
serum dilution, which had to be higher.
Statistical analyses
Comparison  of  means  among  the  four  groups  of 
animals was assessed by one-way analysis of variance 
(ANOVA)  followed  by  Bonferroni’s  test.  Results 
were expressed as mean±SD and p<0.05 considered 
statistically significant and 95% confidence intervals 
of difference were also calculated.
RESULTS
ANOVA  followed  by  Bonferroni’s  test  revealed 
that three groups of mice that were immunized with 
vaccines containing DL-1-MT, had serum anti-HBs 
level much higher than those that were immunized 
with the vaccine without DL-1-MT. Interestingly, no 
statistically significant differences were detected in 
the serum anti-HBs levels among the three groups 
of  mice  that  were  immunized  with  the  vaccines 
containing DL-1-MT at amounts of 1 mg, 10 mg and 
20 mg respectively.
More  precisely,  serum  anti-HBs  level  in  the 
group    of  mice  that  did  not  receive  DL-1-MT 
was  40445±32866  U/ml  and  in  the  groups  that 
received  1 mg, 10 mg and 20 mg of DL-1-MT 
were  2740±1999  U/ml,  3151±3131  U/ml  and 
7089±2488 U/ml. Results are presented graphically 
in figure 1 and the p values and the 95% confidence 
intervals of difference among the groups of mice are 
provided in table 1.
DISCUSSION
While,  effective  vaccines  for  two  of  the  world’s 
leading  killers,  HIV  and  malaria,  remain  in  the 
research stage, effective vaccines against tuberculosis, 
hepatitis  C  and  other  common  infectious  agents 
are still expected and there are many conditions in 
which the efficacy of the already available vaccines 
is diminished. Thus the effort for enhancement of   
the immunogenicity of vaccines continues.
In  the  present  study  it  was  investigated  whether 
inhibition of IDO enhance the immunogenicity of 
a vaccine containing a HBs protein antigen. IDO 
activity  is  considered  to  be  immunosuppressive, 
reduces graft rejection (3), ameliorates the clinical 
course  of  experimental  autoimmune  diseases  (4), 
contributes to success of semi-allogenic pregnancy 
(6) and escape of tumors by immunosurveillance (7).   
Although  many  studies  have  confirmed  that  IDO 
inhibits cell-mediated adaptive immune response (1, 
2), less is known about the effect of IDO on humoral 
adaptive immunity. 
Surprisingly, in the present study inhibition of IDO 
by DL-1-MT did not increase serum anti-HBs levels. 
On the contrary, compared to the three groups of mice 
that were immunized with the vaccines containing 
DL-1-MT, serum anti-HBs level was much higher 
in the mice that were immunized with the vaccine 
without DL-1-MT. Interestingly, the effect of DL-1-
MT was strong regardless of the concentration, since 
no statistically significant differences were detected 
in serum anti-HBs levels among the three groups 
of mice that received 1 mg, 10 mg or 20 mg DL-1-
MT in the vaccines. This could be due to the strong 
inhibitory effect of DL-1-MT on IDO where a small 
dose strongly inhibits IDO activity.
Thus  in  the  simple  experimental  model  used  in 
the present study, inhibition of IDO at the time of 
vaccination  decreased  humoral  adaptive  immune 
response.  Although  the  effect  of  IDO  on  cell-
mediated  adaptive  immunity  has  been  studied  to 
a great extent, its’ effect on humoral immunity is 
much less studied. In a model of nephrotoxic serum 
glomerulonephritis, although DL-1-MT exacerbated 
the disease by enhancing Th1 response, it significantly 
decreased  antigen  specific  IgG1  levels  (11).  The 
effect of IDO inhibition on humoral immunity has 
been evaluated in more detail in an elegant study 
that used the K/BxN murine rheumatoid arthritis 
model and it has been shown that IDO drives B-
cell-mediated autoimmunity (12).  In the reported 
study  IDO  inhibition  by  administration  of  DL-
1-MT  did  not  exacerbate  arthritis  symptoms,  but 
ameliorated symptoms. Alleviation of arthritis was 
not due an altered T-cell response, since Th1, Th2, 
Th17 and Tregs were unaffected, but autoreactive 
B-cell  response  was  diminished,  demonstrating  a 
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role for IDO in stimulating B-cell response. DL-
1-MT reduced the number of reactive to the self-
antigen antibody-secreting cells leading to a great 
decrease of autoantibody titers. Importantly, DL-1-
MT exposure only during the initiation of arthritis 
diminished  the  subsequent  pathogenic  B-cell 
response and alleviated arthritis. These results are in 
accordance with findings of this study, where it was 
found that early administration of DL-1-MT, within 
the vaccine, decreased the antibody response to the 
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fIGURE LEGENDS 
fig. 1. Serum anti-HBs levels in groups of mice treated with different doses of 
DL-1-MT
TABLE LEGENDS 
Table 1. p values and 95% confidence intervals of difference of serum anti-HBs 
levels in groups of mice treated with different doses of DL-1-MT
FIGURE 1 
Figure 1. Serum anti-HBs levels in groups of mice treated with different doses of DL-1-MT.
Groups Groups Sig.
95% Confidence Interval
Lower Bound Upper Bound
No DL-1-MT
1 mg DL-1-MT .001 12180.10 63230.37
10 mg DL-1-MT <0.001 15189.08 59399.92
20 mg DL-1-MT .001 11250.68 55461.52
1 mg DL-1-MT
No DL-1-MT .001 -63230.37 -12180.10
10 mg DL-1-MT 1.000 -25935.87 25114.40
20 mg DL-1-MT 1.000 -29874.27 21176.00
10 mg DL-1-MT
No DL-1-MT <0.001 -59399.92 -15189.08
1 mg DL-1-MT 1.000 -25114.40 25935.87
20 mg DL-1-MT 1.000 -26043.82 18167.02
20 mg DL-1MT
No DL-1-MT .001 -55461.52 -11250.68
1 mg DL-1-MT 1.000 -21176.00 29874.27
10 mg DL-1-MT 1.000 -18167.02 26043.82
Table 1. p values and 95% confidence intervals of difference of serum anti-HBs levels in groups of mice treated with different doses of 
DL-1-MT.
injected antigen. The exact molecular mechanisms 
remain to be elucidated.  
In  conclusion,  inhibition  of  IDO  at  the  time  of 
vaccination  decreases  humoral  immune  response 
to HBs antigen protein vaccine in BALB/c mice. It 
seems that inhibition of IDO is not a proper approach 
for enhancement of the adaptive immune response 
to vaccines against infectious agents and the idea 
that IDO activity is simply immunosuppressive may 
need to be re-evaluated.
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